Core Viewpoint - A class action lawsuit has been filed against Perrigo Company plc for failing to disclose significant issues related to its infant formula business, leading to investor losses during the specified class period [2][8]. Allegation Details - The lawsuit alleges that Perrigo did not disclose the following critical issues: 1. The infant formula business acquired from Nestlé suffered from significant underinvestment in maintenance and operational improvements [8]. 2. Perrigo needed to make substantial capital and operational expenditures beyond previously stated cost estimates to remediate the infant formula business [8]. 3. There were significant manufacturing deficiencies in the facility for the infant formula business [8]. 4. As a result of these issues, the Company's financial results, including earnings and cash flow, were overstated [8]. Financial Impact - On November 5, 2025, Perrigo announced disappointing financial results for Q3 2025, leading to a significant reduction in its fiscal year 2025 outlook due to "infant formula industry dynamics" [8]. - The same day, Perrigo initiated a strategic review of its infant formula business, reassessing a previously announced investment of $240 million, indicating the business had become "less strategic" [8]. - Following this announcement, Perrigo's stock price fell by $5.09, or 25.2%, closing at $15.10 per share on November 5, 2025 [8].

Core Viewpoint - A class action lawsuit has been filed against Firefly Aerospace Inc. for allegedly misleading investors regarding the company's IPO and subsequent financial performance [7]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Firefly common stock during the IPO on August 7, 2025, and those who acquired shares between August 7, 2025, and September 29, 2025 [7]. - Investors have until January 12, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [7]. Group 2: Allegations - The complaint alleges that the Offering Documents related to the IPO were negligently prepared, failing to disclose critical information about the company's operations and growth prospects [7]. - Specific allegations include overstated demand for Firefly's Spacecraft Solutions, overstated operational readiness of the Alpha rocket program, and the potential negative impact on the company once these issues were revealed [7]. Group 3: Financial Impact - Following disappointing financial results reported on September 22, 2025, Firefly's stock price fell by $7.58 per share, or 15.31%, closing at $41.94 on September 23, 2025 [7]. - On September 29, 2025, after disclosing an incident with the Alpha Flight 7 rocket, the stock price dropped by $7.66 per share, or 20.73%, closing at $29.30 on September 30, 2025 [7]. - As of the filing of the complaint, Firefly's stock continues to trade significantly below the $45.00 per share Offering price, indicating substantial losses for investors [7].

Core Viewpoint - A class action lawsuit has been filed against CarMax, Inc. for allegedly making false and misleading statements regarding its growth prospects during the Class Period from June 20, 2025, to September 24, 2025, leading to investor losses [5]. Allegation Details - The lawsuit claims that CarMax's management overstated the company's growth potential, attributing earlier growth in fiscal year 2026 to temporary factors related to customer behavior influenced by tariff speculation [5]. - It is alleged that the statements made by the defendants about CarMax's business operations and future prospects were materially false and misleading [5]. Financial Performance - On April 10, 2025, CarMax reported its fourth quarter and fiscal year 2025 results, which missed consensus estimates, leading to a stock price drop of $13.61, or 17%, closing at $66.45 per share [5]. - On September 25, 2025, CarMax disclosed significant declines in revenue and profit, including a 6.0% revenue decline, a 7.2% decline in total retail used vehicle revenues, and a 5.6% decline in total gross profit, resulting in a further stock price drop of $11.45, or 20.1%, closing at $45.60 per share [5].

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. for allegedly making false and misleading statements regarding its products, particularly the G6 and G7 glucose monitoring devices, during the class period from July 26, 2024, to September 17, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the Southern District of New York on behalf of all individuals and entities who purchased DexCom securities during the specified class period [2]. - Investors have until December 26, 2025, to apply to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that DexCom made unauthorized design changes to the G6 and G7 devices that were not approved by the FDA, which compromised their reliability and posed health risks to users [3]. - It is claimed that the enhancements to the G7 were overstated, and the company downplayed the severity of issues related to the devices, leading to increased regulatory scrutiny and potential legal repercussions [3]. Group 3: Next Steps for Investors - Investors who suffered losses or have information regarding the claims are encouraged to contact the law firm for further details and assistance [4].

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors regarding the safety and efficacy of its Novum LVP devices, which reportedly suffered systemic defects leading to serious patient risks [3][7]. Allegation Details - The lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP, which caused malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures [3]. - The company’s statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs are claimed to be materially false and misleading [3]. Next Steps - Investors who purchased Baxter shares and suffered losses are encouraged to contact the law firm for more information about their rights and potential claims [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is December 15, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across various courts [5].

Core Viewpoint - A class action lawsuit has been filed against Fly-E Group, Inc. for allegedly misleading investors regarding its revenue outlook and sales performance during the class period from July 15, 2025, to August 14, 2025 [7]. Allegation Details - The lawsuit claims that Fly-E's management created a false impression of reliable information about the company's projected revenue and sales, while the actual demand for its electric vehicle products fell short [7]. - The complaint highlights that Fly-E's optimistic revenue goals were not met, and risks associated with lithium batteries, supply chain changes, and regulatory environments were downplayed [7]. - A significant 32% decrease in net revenue was reported, attributed to a decline in total units sold due to customer hesitance linked to lithium battery explosion incidents [7]. Financial Impact - Following the SEC filing on August 14, 2025, which disclosed the revenue decrease, Fly-E's stock price plummeted from $7.76 per share to $1.00 per share, marking an approximate 87% decline in just one day [7]. Next Steps - Investors who purchased Fly-E shares during the class period and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4].

Core Viewpoint - Johnson Fistel, PLLP is investigating FMC Corporation for potential breaches of fiduciary duties and violations of federal securities laws related to misleading statements and undisclosed adverse facts about the company's operations and prospects [1][2]. Group 1: Investigation Details - A class action complaint has been filed against FMC Corporation, alleging that the defendants made materially false and misleading statements and failed to disclose significant adverse facts about the company's business [2]. - Specific allegations include that FMC's channel management initiatives were not progressing as announced, the company avoided sales opportunities due to pricing pressure, and as a result, inventory levels in Latin America, Asia, Canada, and Eastern Europe became inflated [2]. Group 2: Shareholder Rights - Current stockholders who held FMC stock before November 16, 2023, are encouraged to contact Johnson Fistel to discuss their legal rights regarding the investigation [3]. - Johnson Fistel, PLLP is a nationally recognized law firm that represents individual and institutional investors in shareholder derivative and securities class action lawsuits [3].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against CarMax, Inc. for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The investigation is focused on whether CarMax has engaged in practices that may have harmed investors, particularly in light of recent financial disclosures [1][2]. Financial Performance - On April 10, 2025, CarMax reported its fourth quarter and fiscal year 2025 results, missing consensus estimates and removing long-term revenue, unit sales, and market share goals due to macroeconomic factors, leading to a stock price drop of $13.61 (17%) to $66.45 per share [6]. - On September 25, 2025, CarMax disclosed significant year-over-year declines in revenue and profit, including a 6.0% revenue decline, a 7.2% decline in total retail used vehicle revenues, and a 5.6% decline in total gross profit, attributed to inventory adjustments and a $71.3 million increase in loan loss provisions, causing shares to fall by $11.45 (20.1%) to $45.60 per share [6].

Core Viewpoint - A class action lawsuit has been filed against Fly-E Group, Inc. for allegedly misleading investors regarding its revenue outlook and sales performance during the class period from July 15, 2025, to August 14, 2025 [7]. Allegation Details - The lawsuit claims that Fly-E's management created a false impression of reliable revenue projections and demand for its electric vehicle (EV) products, while downplaying risks associated with lithium batteries and supply chain issues [7]. - A significant 32% decrease in net revenue was reported, attributed to a decline in total units sold, as consumer confidence was affected by incidents of lithium battery explosions [7]. - Following the negative news, Fly-E's stock price plummeted approximately 87%, from $7.76 per share to $1.00 per share in one day [7]. Next Steps - Investors who acquired Fly-E shares during the class period and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information and to discuss their legal rights [4][8].

Core Viewpoint - A class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making materially false and misleading statements regarding its product Pylarify and its competitive position during the specified class period [3][7]. Allegation Details - The lawsuit claims that Lantheus provided overly positive statements while concealing adverse facts about Pylarify's competitive position [3]. - It is alleged that Lantheus was not adequately equipped to assess pricing and competitive dynamics for Pylarify [3]. - The company reportedly failed to disclose that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, jeopardizing Pylarify's price point and growth potential [3]. - As a result, the statements made by the defendants regarding the company's business and prospects were materially false and misleading [3]. Next Steps - Investors who purchased Lantheus shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 10, 2025 [7].